Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma

Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma ( Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain )
25 Sep 2020

Latest updates to the ESMO bone health guidelines

Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020

Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort

Professor Jean-Yves Blay and Professor Florence Duffaud
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2019

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )
25 Sep 2019